11,599 Shares in SI-BONE, Inc. (NASDAQ:SIBN) Bought by ProShare Advisors LLC

ProShare Advisors LLC acquired a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,599 shares of the company’s stock, valued at approximately $163,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Mainstream Capital Management LLC bought a new stake in SI-BONE during the 4th quarter worth about $53,000. KLP Kapitalforvaltning AS bought a new stake in SI-BONE during the 4th quarter worth about $97,000. Proficio Capital Partners LLC bought a new stake in SI-BONE during the 4th quarter worth about $155,000. AlphaQuest LLC lifted its position in SI-BONE by 13,950.6% during the 4th quarter. AlphaQuest LLC now owns 11,662 shares of the company’s stock worth $164,000 after buying an additional 11,579 shares in the last quarter. Finally, Aquatic Capital Management LLC lifted its position in SI-BONE by 83.7% during the 4th quarter. Aquatic Capital Management LLC now owns 12,126 shares of the company’s stock worth $170,000 after buying an additional 5,526 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Stock Down 0.6%

Shares of SIBN stock opened at $18.86 on Monday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The firm’s 50-day moving average is $15.62 and its 200-day moving average is $15.34. The stock has a market cap of $803.72 million, a price-to-earnings ratio of -20.50 and a beta of 0.82. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $20.05.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to analysts’ expectations of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Sell-side analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insider Buying and Selling at SI-BONE

In other news, CEO Laura Francis sold 5,412 shares of the firm’s stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $19.49, for a total transaction of $105,479.88. Following the transaction, the chief executive officer now directly owns 490,987 shares of the company’s stock, valued at approximately $9,569,336.63. This trade represents a 1.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Anshul Maheshwari sold 4,937 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $17.00, for a total value of $83,929.00. Following the completion of the sale, the chief financial officer now owns 265,356 shares of the company’s stock, valued at approximately $4,511,052. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,565 shares of company stock valued at $1,669,871 in the last three months. 4.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SIBN shares. Needham & Company LLC reissued a “buy” rating and set a $24.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial boosted their price target on shares of SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.